Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial
Conclusions:
SCIg is well-tolerated, safe, and effective in mild to moderate MG exacerbation. Comparative safety and efficacy must be established with randomized controlled trials.
Classification of evidence:
This study provides Class IV evidence that in patients with mild to moderate MG exacerbation, SCIg is safe and effective in reducing MG disability measures.
Source: Neurology - Category: Neurology Authors: Beecher, G., Anderson, D., Siddiqi, Z. A. Tags: Outcome research, Myasthenia, All Clinical trials, Patient safety, Class IV ARTICLE Source Type: research
More News: Brain | Clinical Trials | Disability | Headache | Migraine | Myasthenia Gravis | Neurology | Study